דרלין

אני מקבלת את התרופה דרלין ללחץ דם גבוה במינון של 80 מ"ג- סלואו דרלין. לאחרונה קראתי שהתרופה דרלין גורמת להשמנה. שאלתי אליכם אם באמת גורם הדרלין להשמנה או להגברת התיאבון. בתודה מקרב לב חיה

שלום חיה, אכן, תיתכן עליית-מה במשקל בקרב המשתמשים בתרופה דרלין. ראוי, בהקשר זה, לציין את העובדה ששימוש בתרופה אחרת המשמשת למניעת מיגרנות - טופמקס - כרוך בנטייה לירידה במשקל. ניתן לקרוא על כך, לדוגמא, ב-2 התקצירים המצורפים כאן. מפתח לשמות התרופות המופיעות בתקצירים amitriptyline = אלטרול/אלטרולט propranolol = דרלין topiramate = טופמקס atenolol = נורמיטן/נורמלול verapamil = איקקור / איקפרס / וראפרס http://www.ncbi.nlm.nih.gov/pubmed/18640463 Clin Ther. 2008 Jun;30(6):1069-80. Weight change associated with the use of migraine-preventive medications. Taylor FR. Park Nicollet Headache Clinic & Research Center and the University of Minnesota School of Medicine, Minneapolis, Minnesota 55426, USA. [email protected] Abstract BACKGROUND: Medications administered long term, such as those used for migraine prophylaxis, are often associated with weight change as a side effect. Such effects may compromise general health status, exacerbate coexisting medical conditions, and affect medication adherence. Weight gain should be of particular concern in patients with migraine, as there is evidence that overweight and obese patients with migraine are at risk for an increased frequency and severity of migraine attacks. OBJECTIVE: This article reviews weight-change data from recent clinical studies of migraine-preventive medications in children, adolescents, and adults with migraine. METHODS: A PubMed search was conducted for English-language articles published between January 1970 and November 2007. Among the search terms were migraine prevention, migraine prophylaxis, migraine treatment, antidepressant drug, beta-adrenergic-receptor blockers, antiepileptic drug, anticonvulsant drug, weight gain, and weight loss. Studies that reported weight-change data (gain, loss, or neutral) were included. When available, double-blind, placebo-controlled studies were selected for review. Open-label, retrospective or prospective trials may also have been included. RESULTS: Most of the migraine-preventive medications classified by the United States Headache Consortium as group 1 based on the high level of evidence for their efficacy--for instance, amitriptyline, propranolol, and divalproex sodium-have been associated with varying degrees of weight gain. The exceptions are timolol, which is weight neutral, and topiramate, which is associated with weight loss. Among the drugs that have been associated with weight gain, a higher incidence of weight gain was observed with amitriptyline and divalproex sodium than with propranolol. CONCLUSION: Weight-change effects require careful consideration when selecting migraine-preventive medications, and weight should be monitored carefully over the course of any migraine treatment plan http://www.ncbi.nlm.nih.gov/pubmed/16362700 J Headache Pain. 2005 Sep;6(4):322-4. Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. Maggioni F, Ruffatti S, Dainese F, Mainardi F, Zanchin G. Headache Centre, Department of Neurosciences, University of Padua, Via Giustiniani 3, I-35128, Padua, Italy. [email protected] Abstract We conducted a study on 367 patients (86% female, 14% male; mean age 37+/-15 years) suffering from migraine with and without aura and chronic tension-type headache to evaluate the incidence of weight gain, an undesirable side effect observed during prophylactic therapy in primary headaches. Patients treated with amitriptyline (20 and 40 mg), pizotifen (1 mg), propranolol (80-160 mg), atenolol (50-100 mg), verapamil (160-240 mg), valproate (600 mg) and gabapentin (900-1200 mg) were evaluated after a period of 3 and 6 months. In particular, 89 patients were assessed (78% female, 22% male) at 6 months, of whom 10 were in treatment with amitriptyline 20 mg, 19 with amitriptyline 40 mg, 7 with pizotifen (1 mg), 13 with propranolol (80-160 mg), 4 with verapamil (160 mg), 10 with valproate (600 mg), 15 with atenolol (50 mg) and 11 with gabapentin (900-1200 mg). The control group consisted of 97 patients with migraine (79% female, 21% male; mean age 35+/-16 years) without indication for prophylactic therapy. Weight variations >or=1 kg were considered. After 6 months of therapy, the percentage of patients with weight gain was 86% with pizotifen (6/7; mean weight increase 4.4+/-2.5 kg), 60% with amitriptyline 20 mg (6/10; 3.1+/-1.6), 47% with amitriptyline 40 mg (9/19; 5.4+/-2.7), 25% with valproate 600 mg (2/8, 3.0+/-2.8 kg), 25% with verapamil (1/4, 2.5 kg), 20% with atenolol (3/15, 1.7+/-0.6 kg), 9% with gabapentin (1/11, 1.5 kg) and 8% with propranolol (1/13; 6 kg). We conclude that propranolol, gabapentin, atenolol, verapamil and valproate affect body weight in a modest percentage of patients at 6 months. A greater mean weight gain at 6 months was found in patients treated with pizotifen, amitriptyline, and, in one patient out of 13, with propranolol